Galunisertib Recruiting Phase 2 Trials for Prostate Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0062462 (Prostate Cancer)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
https://clinicaltrials.gov/ct2/show/	Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer	Enzalutamide (DB08899) Galunisertib (DB11911)